option care health - OPCH
OPCH
Close Chg Chg %
21.88 -0.09 -0.43%
Open Market
21.79
-0.09 (0.43%)
Volume: 328.36K
Last Updated:
Nov 21, 2024, 10:29 AM EDT
Company Overview: option care health - OPCH
OPCH Key Data
| Open $21.81 | Day Range 21.68 - 21.96 |
| 52 Week Range 21.39 - 34.52 | Market Cap $3.72B |
| Shares Outstanding 170.18M | Public Float 168.20M |
| Beta 1.32 | Rev. Per Employee N/A |
| P/E Ratio 18.32 | EPS $1.20 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.69M |
OPCH Performance
| 1 Week | -0.23% | ||
| 1 Month | -25.70% | ||
| 3 Months | -31.26% | ||
| 1 Year | -27.55% | ||
| 5 Years | 68.31% |
OPCH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
10
Full Ratings ➔
About option care health - OPCH
Option Care Health, Inc. engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Its home infusion services consist of anti-infectives, nutrition support, bleeding disorder therapies, immunoglobulin therapy, and other therapies for chronic and acute conditions. The company was founded in 1996 and is headquartered in Bannockburn, IL.
OPCH At a Glance
Option Care Health, Inc.
3000 Lakeside Drive
Bannockburn, Illinois 60015
| Phone | 1-312-940-2443 | Revenue | 4.30B | |
| Industry | Medical/Nursing Services | Net Income | 267.09M | |
| Sector | Health Services | 2023 Sales Growth | 9.065% | |
| Fiscal Year-end | 12 / 2024 | Employees | 5,809 | |
| View SEC Filings |
OPCH Valuation
| P/E Current | 18.316 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 22.751 |
| Price to Sales Ratio | 1.412 |
| Price to Book Ratio | 4.137 |
| Price to Cash Flow Ratio | 16.367 |
| Enterprise Value to EBITDA | 18.311 |
| Enterprise Value to Sales | 1.604 |
| Total Debt to Enterprise Value | 0.169 |
OPCH Efficiency
| Revenue/Employee | 740,630.745 |
| Income Per Employee | 45,978.654 |
| Receivables Turnover | 10.002 |
| Total Asset Turnover | 1.312 |
OPCH Liquidity
| Current Ratio | 1.77 |
| Quick Ratio | 1.327 |
| Cash Ratio | 0.556 |
OPCH Profitability
| Gross Margin | 21.431 |
| Operating Margin | 7.312 |
| Pretax Margin | 8.338 |
| Net Margin | 6.208 |
| Return on Assets | 8.142 |
| Return on Equity | 19.025 |
| Return on Total Capital | 10.32 |
| Return on Invested Capital | 10.516 |
OPCH Capital Structure
| Total Debt to Total Equity | 82.045 |
| Total Debt to Total Capital | 45.069 |
| Total Debt to Total Assets | 35.045 |
| Long-Term Debt to Equity | 80.337 |
| Long-Term Debt to Total Capital | 44.13 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Option Care Health - OPCH
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 3.03B | 3.44B | 3.94B | 4.30B | |
Sales Growth
| +31.26% | +13.39% | +14.72% | +9.06% | |
Cost of Goods Sold (COGS) incl D&A
| 2.42B | 2.72B | 3.14B | 3.38B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 96.71M | 83.97M | 85.15M | 62.20M | |
Depreciation
| 61.58M | 50.78M | 51.96M | 27.82M | |
Amortization of Intangibles
| 35.13M | 33.19M | 33.19M | 34.38M | |
COGS Growth
| +30.82% | +12.41% | +15.29% | +7.71% | |
Gross Income
| 610.95M | 716.55M | 806.35M | 922.02M | |
Gross Income Growth
| +33.02% | +17.28% | +12.53% | +14.34% | |
Gross Profit Margin
| +20.15% | +20.84% | +20.44% | +21.43% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 500.20M | 525.71M | 566.12M | 607.43M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 500.20M | 525.71M | 566.12M | 607.43M | |
SGA Growth
| +15.67% | +5.10% | +7.69% | +7.30% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 28.12M | 24.93M | (1.09M) | (52.97M) | |
EBIT after Unusual Expense
| 82.63M | 165.92M | 241.32M | 367.57M | |
Non Operating Income/Expense
| 3.32M | 6.04M | 19.34M | 53.40M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 3.31M | 6.03M | 5.13M | 5.53M | |
Interest Expense
| 91.19M | 55.46M | 54.90M | 62.22M | |
Interest Expense Growth
| +24.25% | -39.18% | -1.02% | +13.35% | |
Gross Interest Expense
| 91.19M | 55.46M | 54.90M | 62.22M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (5.24M) | 116.49M | 205.77M | 358.74M | |
Pretax Income Growth
| +93.29% | +2,321.90% | +76.63% | +74.34% | |
Pretax Margin
| -0.17% | +3.39% | +5.22% | +8.34% | |
Income Tax
| 2.83M | (23.40M) | 55.21M | 91.65M | |
Income Tax - Current - Domestic
| 1.64M | 6.82M | 13.29M | 76.73M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 1.20M | (30.22M) | 41.93M | 14.93M | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| 3.31M | 6.03M | 5.13M | 5.53M | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (8.08M) | 139.90M | 150.56M | 267.09M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (8.08M) | 139.90M | 150.56M | 267.09M | |
Net Income Growth
| +89.36% | +1,832.27% | +7.62% | +77.40% | |
Net Margin Growth
| -0.27% | +4.07% | +3.82% | +6.21% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (8.08M) | 139.90M | 150.56M | 267.09M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (8.08M) | 139.90M | 150.56M | 267.09M | |
EPS (Basic)
| -0.0446 | 0.7778 | 0.8313 | 1.4924 | |
EPS (Basic) Growth
| +90.82% | +1,843.95% | +6.88% | +79.53% | |
Basic Shares Outstanding
| 180.97M | 179.85M | 181.10M | 178.97M | |
EPS (Diluted)
| -0.0446 | 0.772 | 0.8269 | 1.4808 | |
EPS (Diluted) Growth
| +90.82% | +1,830.94% | +7.11% | +79.08% | |
Diluted Shares Outstanding
| 180.97M | 181.21M | 182.07M | 180.38M | |
EBITDA
| 207.47M | 274.81M | 325.38M | 376.80M | |
EBITDA Growth
| +98.64% | +32.46% | +18.40% | +15.80% | |
EBITDA Margin
| +6.84% | +7.99% | +8.25% | +8.76% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 31.375 | |
| Number of Ratings | 10 | Current Quarters Estimate | 0.355 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 1.311 | |
| Last Quarter’s Earnings | 0.41 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 1.48 | Next Fiscal Year Estimate | 1.333 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 5 | 8 | 8 |
| Mean Estimate | 0.35 | 0.27 | 1.31 | 1.33 |
| High Estimates | 0.40 | 0.31 | 1.53 | 1.71 |
| Low Estimate | 0.32 | 0.20 | 1.18 | 1.12 |
| Coefficient of Variance | 7.05 | 16.77 | 10.77 | 13.71 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 8 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 2 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Option Care Health - OPCH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Option Care Health - OPCH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 23, 2024 | Timothy P. Sullivan Director | 20,814 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.91 per share | 643,360.74 |
| Aug 23, 2024 | Elizabeth Quadros Betten Director | 21,339 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.09 per share | 663,429.51 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 7,158 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 4,306 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 1,226 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 43,428 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.42 per share | 1,364,507.76 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 49,193 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $28.86 per share | 1,419,709.98 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 46,807 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $23.96 per share | 1,121,495.72 |
| Aug 20, 2024 | Michael Bavaro Chief Human Resources Officer | 44,654 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $18.97 per share | 847,086.38 |
| May 22, 2024 | Collin G. Smyser GC & Corporate Secretary | 42,120 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 22, 2024 | Collin G. Smyser GC & Corporate Secretary | 41,882 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $29.78 per share | 1,247,245.96 |
| May 22, 2024 | Collin G. Smyser GC & Corporate Secretary | 1,624 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 22, 2024 | Christopher Grashoff Chief Growth Officer | 26,275 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $29.78 per share | 782,469.50 |
| May 13, 2024 | R. Carter Pate Director | 99,608 | Bona fide gift | 0.00 |
| May 13, 2024 | Femi Adewunmi Chief Medical Officer | 9,867 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 13, 2024 | Luke Whitworth Chief Operating Officer | 117,880 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.34 per share | 3,812,239.20 |
| Feb 29, 2024 | Harry M. Jansen Kraemer Director | 269,528 | Open market or private purchase of non-derivative security Non-derivative transaction at $31.55 per share | 8,503,608.40 |
| Feb 28, 2024 | Michael H. Shapiro Chief Financial Officer | 247,317 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.24 per share | 7,973,500.08 |
| Feb 28, 2024 | John C. Rademacher Chief Executive Officer; Director | 596,399 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.24 per share | 19,227,903.76 |
| Feb 27, 2024 | Luke Whitworth Chief Operating Officer | 127,051 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $32.24 per share | 4,096,124.24 |